Product Transfer: Is a Transfer Plan a required GMP Document?
Recommendation
29/30 October 2024
Organisation of a GMP-compliant Site Change
A frequently asked question in product/technology transfer courses is: is a transfer plan a required GMP document?
The question whether a Transfer Plan is a "must have document" from a GMP point of view is already answered with "yes" in the Transfer SOP in most pharmaceutical companies. It should be mentioned here that the aforementioned Transfer SOP is also a "must document" insofar as products are to be transferred, i.e. taken into production or transferred to another manufacturing site.
The times when products were transferred by faxing the manufacturing instructions alone are long gone. Since the major amendment of Chapter 4 of the EU GMP Guide in 2011, the Transfer Plan as well as the Transfer SOP have been included in the list of required documents. Chapter 4.29 states:
"There should be written policies, procedures, protocols, reports and the associated records of actions taken or conclusions reached, where appropriate, for the following examples: [...] - Technology transfer [...]."
"Procedure" means SOP, "protocol" stands for plan.
As expected from a GMP Guideline, there is no indication of the level of detail. These should be described in the Transfer SOP. As a rule, information on the transfer itself (which product, which sites), on the responsibilities and, if applicable, on the regulatory strategy is expected here. Also important are details on the release of the batches produced in the receiving site and which criteria must be fulfilled for the transfer process to be considered complete.
Many other documents are required or useful in a product transfer, but are not considered GMP-required. However, they can be helpful in inspections and audits. These include, for example, project schedules, lists of documents handed over, EHS assessments, etc. However, one should not forget the documents that are essential for a transfer from a GMP perspective: change control on the donor and receiving side.
Related GMP News
23.10.2024Warning Letter to Indian sterile Manufacturer due to Cross-Contamination and Particles
16.10.2024Do Parenterals have to be 100% free of Particles?
02.10.2024Does Purified Water have to be tested for Endotoxins?
18.09.2024FDA issues Warning Letter to Cell Gene Therapy manufacturer
11.09.2024Humidity in pharmaceutical Cleanroom Walls after a Leakage
28.08.2024FDA Warning Letter to pharmaceutical Manufacturer in Puerto Rico